Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 1958-1965

  Kumar, Santosh ^a   Liu, Hong ^b   Halpert, James R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2BETA HYDROXYTESTOSTERONE; 6BETA HYDROXYTESTOSTERONE; 7 BENZYLOXY 4 (TRIFLUOROMETHYL)COUMARIN; 7 BENZYLOXYQUINOLINE; COUMARIN DERIVATIVE; CUMENE HYDROPEROXIDE; CYTOCHROME B5; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; F228I ENZYME; HYDROGEN PEROXIDE; L216W ENZYME; MUTANT PROTEIN; QUINOLINE DERIVATIVE; T309A ENZYME; T309V ENZYME; T433S ENZYME; TESTOSTERONE; TESTOSTERONE DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CELL SUSPENSION; CONTROLLED STUDY; DEBENZYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; MOLECULAR EVOLUTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

BENZENE DERIVATIVES; COUMARINS; CYTOCHROME P-450 CYP3A; DIRECTED MOLECULAR EVOLUTION; HYDROGEN PEROXIDE; MUTAGENESIS, SITE-DIRECTED; OXIDATION-REDUCTION; QUINOLINES; TESTOSTERONE;

EID: 33751542716     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012054     Document Type: Article

References (41)

1. Apletalina EV and Davydov DR (1997) Effect of cytochrome b(5) on thermodynamic parameters pf substrate binding and spin transitions in cytochrome P450 2B4. FASEB J 11:A791-A791 P116.
2. Bridges A, Gruenke L, Chang YT, Vakser IA, Loew G, and Waskel L (1998) Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 273:17036-17049.
3. Chefson A, Zhao J, and Auclair K (2006) Replacement of natural cofactors by selected hydrogen peroxide donors or organic peroxides results in improved activity for CYP3A4 and CYP2D6. Chembiochem 7:916-919.
4. Cirino PC, Mayer KM, and Umeno D (2003) Generating mutant libraries using error-prone PCR. Methods Mol Biol 231:3-9.
5. Coon MJ (2005) Cytochrome P450: nature's most versatile biological catalyst. Annu Rev Pharmacol Toxicol 45:1-25.
6. Davydov DR, Fernando H, Baas BJ, Sligar SG, and Halpert JR (2005) Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry 44:13902-13913.
7. DeLano WL (2004) The PyMol User's Manual. DeLano Scientific LLC, San Carlos, CA.
8. Domanski TL and Halpert JR (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117-137.
9. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, and Halpert JR (2001) Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150-10160.
10. Ekins S, Stresser DM, and Williams JA (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24:161-166.
11. Gillam EM (2005) Exploring the potential of xenobiotic-metabolising enzymes as biocatalysts: evolving designer catalysts from polyfunctional cytochrome P450 enzymes. Clin Exp Pharmacol Physiol 32:147-152.
12. Glieder A, Farinas ET, and Arnold FH (2002) Laboratory evolution of a soluble, self-sufficient, highly active alkane hydroxylase. Nat Biotechnol 20:1135-1139.
13. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
14. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402.
15. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636-6641.
16. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
17. Jushchyshyn MI, Hutzler JM, Schrag ML, and Wienkers LC (2005) Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys 438:21-28.
18. Keizers PH, Schraven LH, de Graaf C, Hidestrand M, Ingelman-Sundberg M, van Dijk BR, Vermeulen NP, and Commandeur JN (2005) Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochem Biophys Res Commun 338:1065-1074.
19. Kim D and Guengerich FP (2004) Enhancement of 7-methoxyresorufin O-demethylation activity of human cytochrome P450 1A2 by molecular breeding. Arch Biochem Biophys 432:102-108.
20. Kumar S, Chen CS, Waxman DJ, and Halpert JR (2005a) Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem 280:19569-19575.
21. Kumar S, Davydov DR, and Halpert JR (2005b) Role of cytochrome B5 in modulating peroxide-supported CYP3A4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab Dispos 33:1131-1136.
22. Kumar S and Halpert JR (2005) Use of directed evolution of mammalian cytochromes P450 for investigating the molecular basis of enzyme function and generating novel biocatalysts. Biochem Biophys Res Commun 338:456-464.
23. Kumar S, Scott EE, Liu H, and Halpert JR (2003) A rational approach to re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of P450 2C5. J Biol Chem 278:17178-17184.
24. Meinhold P, Peters MW, Chen MM, Takahashi K, and Arnold FH (2005) Direct conversion of ethane to ethanol by engineered cytochrome P450 BM3. Chembiochem 6:1765-1768.
25. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162.
26. Otey CR, Bandara G, Lalonde J, Takahashi K, and Arnold FH (2006) Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol Bioeng 93:494-499.
27. Park H, Lee S, and Suh J (2005) Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. J Am Chem Soc 127:13634-13642.
28. Raag R, Martinis SA, Sligar SG, and Poulos TL (1991) Crystal structure of the cytochrome P-450CAM active site mutant Thr252Ala. Biochemistry 30:11420-11429.
29. Reed JR and Hollenberg PF (2003) Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5. J Inorg Biochem 93:152-160.
30. Schenkman JB and Jansson I (2003) The many roles of cytochrome b5. Pharmacol Ther 97:139-152.
31. Schoemaker HE, Mink D, and Wubbolts MG (2003) Dispelling the myths - biocatalysis in industrial synthesis. Science (Wash DC) 299:1694-1697.
32. Scott EE and Halpert JR (2005) Structures of cytochrome P450 3A4. Trends Biochem Sci 30:5-7.
33. Tanaka T, Okuda T, and Yamamoto Y (2004) Characterization of the CYP3A4 active site by homology modeling. Chem Pharm Bull (Tokyo) 52:830-835.
34. Vail RB, Homann MJ, Hanna I, and Zaks A (2005) Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J Ind Microbiol Biotechnol 32:67-74.
35. Vaz AD, McGinnity DF, and Coon MJ (1998) Epoxidation of olefins by cytochrome P450: evidence from site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant. Proc Natl Acad Sci USA 95:3555-3560.
36. Vaz AD, Pernecky SJ, Raner GM, and Coon MJ (1996) Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonin-302 to alanine mutagenesis of cytochrome P450 2B4. Proc Natl Acad Sci USA 93:4644-4648.
37. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science (Wash DC) 305:683-686.
38. Yamaguchi Y, Khan KK, He YA, He YQ, and Halpert JR (2004) Topological changes in the CYP3A4 active site probed with phenyldiazene: effect of interaction with NADPH-cytochrome P450 reductase and cytochrome b5 and of site-directed mutagenesis. Drug Metab Dispos 32:155-161.
39. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita K, and Kamataki T (2003) Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66:2333-2340.
40. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094.
41. Zhang Y and Pernecky SJ (1999) Cumene hydroperoxide-supported demethylation reactions catalyzed by cytochrome P450 2B4 lacking the NH2-terminal sequence. Biochem Biophys Res Commun 258:32-38.